SCHEMBL6993767

SCHEMBL6993767

CC(=O)Nc1ccc(C(=O)NCCN2CC3CC(C2)CN(CC(O)COc2ccc(C#N)cc2)C3)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.51
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GAA P10253 1/20 0.46
MAPT P10636 6/20 0.45
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
RAB9A P51151 1/20 0.45
POLB P06746 2/20 0.45
RECQL P46063 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HTT P42858 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
USP2 O75604 1/20 0.42
NAMPT P43490 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6989049 0.90 NAMPT (0.41) KCNH2SMN1; SMN2L3MBTL1POLBHTT
SCHEMBL6995821 0.89 KCNH2 (0.53) KCNH2POLBNAMPTHRH2HRH1
SCHEMBL7030896 0.89 NAMPT (0.41) KCNH2TSHRHSD17B10MAPTLMNA
SCHEMBL7036069 0.88 KCNH2 (0.52) KCNH2MAPTL3MBTL1POLBMEN1
SCHEMBL6989327 0.85 KCNH2 (0.49) KCNH2MAPTLMNARAB9APOLB
SCHEMBL7030903 0.85 NAMPT (0.40) KCNH2SMN1; SMN2L3MBTL1POLBHTT
SCHEMBL7031260 0.83 KCNH2 (0.58) KCNH2TSHRHSD17B10MAPTSMN1; SMN2
SCHEMBL6739974 0.80 KCNH2 (0.49) KCNH2TSHRHSD17B10GAAMAPT
SCHEMBL7028488 0.79 CD274 (0.61) RAB9ANAMPTCD274
SCHEMBL6993770 0.78 KDM4E (0.60) KCNH2TSHRMAPTL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E KCNH2 7/4885TSHR 743/4885HSD17B10 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.